We are live on ! Find out more
BBA

Baker Bros. Advisors Portfolio holdings

AUM $17.4B
1-Year Est. Return 131.5%
This Fund
S&P 500
This Quarter Est. Return
+6.87%
1 Year Est. Return
+131.5%
3 Year Est. Return
+336.81%
5 Year Est. Return
+553.16%
10 Year Est. Return
+4,134.93%
AUM
$9.54B
AUM Growth
+$55.8M
Cap. Flow
-$1.48B
Cap. Flow %
-15.48%
Top 10 Hldgs %
82.65%
Holding
142
New
10
Increased
13
Reduced
15
Closed
7

Top Buys

Rank Stock Value
1
NTLA icon
Intellia Therapeutics
NTLA
+$28.3M
2
ACAD icon
Acadia Pharmaceuticals
ACAD
+$10.1M
3
MRUS
Merus
MRUS
+$9.82M
4
AAAP
Advanced Accelerator Applications S.A.
AAAP
+$6.94M
5
ALDR
Alder Biopharmaceuticals
ALDR
+$5.88M

Top Sells

Rank Stock Value
1
ANAC
ANACOR PHARMACEUTICALS INC COM
ANAC
+$274M
2
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$15.9M
3
OMER icon
Omeros
OMER
+$11.5M
4
GBT
Global Blood Therapeutics, Inc.
GBT
+$9.52M
5
IMGN
Immunogen Inc
IMGN
+$9.01M

Sector Composition

Rank Sector Weight
1 Healthcare 80.73%
2 Technology 0.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
OMER icon
126
Omeros
OMER
$845M
– –
-749,250
Closed -$11.5M
ATYR
127
aTyr Pharma
ATYR
$47.4M
– –
-152,686
Closed -$8.42M
APTO
128
DELISTED
Aptose Biosciences, Inc.
APTO
– –
-74
Closed -$100K
GBT
129
DELISTED
Global Blood Therapeutics, Inc.
GBT
– –
-600,000
Closed -$9.52M
ANAC
130
DELISTED
ANACOR PHARMACEUTICALS INC COM
ANAC
– –
-5,122,375
Closed -$274M
2 3 4 5
6

Similar funds

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $17.1B AUM 70.99% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
ASRS
Arizona State Retirement System Phoenix, Arizona $17.1B AUM 30.52% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
VMPIC
Varma Mutual Pension Insurance Co Helsinki, Finland $17B AUM 24.09% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
BCIM
British Columbia Investment Management Victoria, British Columbia, Canada $17B AUM 31.69% 1-Year Est. Return

Baker Bros. Advisors's Q2 2016 Portfolio in Review

As of Q2 2016, Baker Bros. Advisors held 142 positions worth $9.54B, up 0.59% from $9.48B the previous quarter. Its ten largest holdings account for 83% of the portfolio.

Baker Bros. Advisors withdrew a net $1.48B in Q2 2016, closing 7 positions and reducing 15 holdings. Its most notable exit was ANACOR PHARMACEUTICALS INC COM, an estimated $274M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 81% of assets, up from 77% a quarter earlier, followed by Technology.

Against the trend, Baker Bros. Advisors opened a new position in Intellia Therapeutics worth $22.7M.

  • Baker Bros. Advisors's largest Q2 2016 buy was Intellia Therapeutics: 1,062,120 shares worth $22.7M.
  • Baker Bros. Advisors added most to Acadia Pharmaceuticals in Q2 2016, an estimated $10.1M increase.
  • Baker Bros. Advisors's biggest Q2 2016 reduction was Mirati Therapeutics, Inc. Common Stock, cutting an estimated $15.9M.
  • Baker Bros. Advisors fully exited ANACOR PHARMACEUTICALS INC COM in Q2 2016, selling an estimated $274M.
  • Baker Bros. Advisors's ten largest holdings make up 83% of its $9.54B portfolio in Q2 2016.
  • Baker Bros. Advisors opened 10 new positions and closed 7 in Q2 2016.
  • Baker Bros. Advisors's portfolio value rose 0.59% quarter-over-quarter to $9.54B.

Based on Baker Bros. Advisors's 13F filing for Q2 2016, filed 15 Aug 2016.